Please check your internet connection and try again.
# Walethmade bromide
## Overview
**Note:** There is no FDA-approved drug by the name "Walethmade bromide." This query likely refers to a typographical error or a misidentification of **Aclidinium bromide** (a long-acting muscarinic antagonist) or a similar quaternary ammonium compound. The following information applies to **Aclidinium bromide** as a representative agent. If you intended a different drug, please clarify.
## Primary Indications
Maintenance bronchodilator treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
## Adult Dosing
* **Inhalation:** 400 mcg twice daily.
* **Maximum Dose:** 800 mcg/day.
## Pediatric Dosing
Safety and efficacy have not been established in patients younger than 18 years. Use is not recommended.
## Dose Adjustments
* **Hepatic Impairment:** No dosage adjustment indicated; however, monitor closely if systemic absorption occurs.
* **Renal Impairment:** No dosage adjustment indicated.
## Contraindications
* Hypersensitivity to aclidinium bromide, atropine, or derivatives.
* Not indicated for the relief of acute bronchospasm (acute rescue therapy).
## Adverse Effects
* **Common:** Headache, nasopharyngitis, cough.
* **Serious:** Paradoxical bronchospasm (discontinue immediately), anticholinergic effects (urinary retention, acute narrow-angle glaucoma), worsening of prostatic hyperplasia.
## Key Drug Interactions
* **Anticholinergic agents:** Concomitant use with other anticholinergics (e.g., ipratropium, tiotropium) may increase the risk of systemic anticholinergic adverse effects. Avoid concurrent use.
## Monitoring
* **Efficacy:** Serial lung function (FEV1), reduction in rescue inhaler usage, symptomatic improvement in dyspnea.
* **Safety:** Monitor for symptoms of paradoxical bronchospasm, urinary retention, and visual changes suggesting angle-closure glaucoma.
## Clinical Pearls
* **Administration:** Must be administered via a specific dry powder inhaler device. Ensure patient instruction on device technique, as inhalation force influences drug delivery.
* **Patient Education:** Advise patients that the drug is for routine maintenance and will not provide immediate relief during an exacerbation.
* **Systemic Effects:** Although systemic bioavailability is low, educate patients on the signs of systemic anticholinergic toxicity (e.g., dry mouth, blurred vision, constipation).
***
**Educational Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Drug information and prescribing guidelines change frequently. Always consult the latest official manufacturer labeling (Package Insert), clinical guidelines, and institutional policies before prescribing or administering medication.
